Treatment of red cell aplasia in CLL with fludarabine
TO THE EDITOR Berrebi 1 and colleagues reported a case of pure red cell aplasia (PRCA) associated with chronic lymphocytic leukaemia (CLL), successfully treated with fludarabine, cyclosporine A and erythropoietin.
We describe a patient with CLL and long-standing PRCA in whom the red cell aplasia resolved with fludarabine used as a single agent.
A 56-year-old woman was found in February 1991 to have lymphocytosis on a routine blood cell count. There was no lymphadenopathy or hepatosplenomegaly. Peripheral blood morphology and immunological markers were consistent with the diagnosis of B cell CLL. Hb was 12.8 g/dl, WBC 11 × 10 9 /l, lymphocytes 65%, platelets 210 × 10 9 /l. Bone marrow aspirate showed a hypercellular marrow with 82% lymphocytes and 12% erythroid percursors. There was a diffuse lymphoid infiltration and mild fibrosis in the bone marrow trephine biopsy. The patient was diagnosed as CLL stage A and no treatment was given. Three months later the Hb dropped to 6.4 g/dl; lymphocytes were 13.6 × 10 9 /l. A bone marrow aspirate was a dry tap. The trephine biopsy showed no significant changes when compared to the previous one. She was transfused and was given prednisolone for 2 months with no improvement.
The patient was referred to us, 7 months after the diagnosis of CLL. She had been requiring regular red cell support but there was no evidence of disease progression. The Hb was 6.8 g/dl, lymphocytes were 14 × 10 9 /l of which 25% were clonal B cells (CD19
The remainder of cells were T cells with a slight decrease of CD4 + cells. A bone trephine revealed infiltration by mature lymphoid cells, with almost total absence of erythroid precursors. A direct Coombs test was negative and the reticulocyte count was Ͻ0.1%. Cyclosporine A was started at a dose of 5 mg/kg daily which was gradually increased to 8 mg/kg daily, for 4 months with no significant response. Over the following year she was treated with high-dose methylprednisolone, erythropoietin and cyclophosphamide at a dosage of 200 mg/day, three times a week for 5 months with no improvement and she had been requiring regular red cell transfusions, 3 units every 3 weeks with iron kelation therapy.
There was an increase in the spleen size and a splenectomy was performed, with temporary improvement of the red blood cell requirements. Spleen histology showed a moderate expansion of the white pulp with small CD20 + lymphoid cells. The patient remained anaemic (Hb Ͻ9 g/dl) and fludarabine was started in March 1994, at a dose of 25 mg/m 2 daily for 5 days, every 4 weeks for a total of six courses. This treatment was well tolerated and there was a rapid improvement in the Hb levels. After the first course of fludarabine she did not require further blood transfusions. Peripheral blood counts and bone marrow aspirate after the sixth course were consistent with complete remission with Hb 11.2 g/dl, WBC 10.8 × 10 9 /l, Neut 75%, lymphocytes 21%, platelets 435 × 10 phine biopsy showed a hypercellular marrow with few nodular aggregates of lymphoid cells, consistent with nodular partial remission. Over the following 4 years the Hb has remained stable and in the last follow-up in September 1998 peripheral blood counts were: Hb 11.5 g/dl, WBC 13 × 10 9 /l, lymphocytes 11 × 10 9 /l of which only 3% of cells coexpressed CD5 and CD19.
Pure red cell aplasia associated with CLL is probably underdiagnosed as the anemia in this disorder is frequently multifactorial, and other commoner causes such as iron deficiency, marrow infiltration and chemotherapy have to be excluded. In a few cases there is an association with fludarabine treatment, 2 and other cytopenias have also been described with this drug. 3 In the patient described by Berrebi the association of fludarabine with cyclosporine A and erythropoietin resulted in the resolution of PRCA; their patient had not responded, like ours, to the combination of cyclosporine A and erythropoietin. A similar case to ours, remission of PRCA has been reported by Jaccard et al 4 using fludarabine as a single agent. Our patient was initially treated with different immunosuppressive agents with no improvement. The response to fludarabine was prompt and has been sustained for 4 years without further red blood cell transfusion.
T cell-mediated suppression of erythropoiesis has been implicated as the cause of PRCA in CLL. Fludarabine decreases T lymphocytes and this may be the reason for the rapid recovery in this patient. However, it is not clear why in some patients fludarabine treatment has been implicated in the onset of PRCA. Further studies of the immunological complications during treatment with purine antimetabolites will possibly explain these interesting associations.
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